Investors Home

Access Q1 2021 Financial Results Webcast

Thursday, May 6, 2021 · 4:30pm ET 

Download Investor Presentation 

 

Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). 

The Company launched its first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), in September 2020. Phexxi is the first and only hormone-free, prescription contraceptive vaginal gel. Learn more at phexxi.com.  

The Company is evaluating its investigational drug candidate EVO100 (L-lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of urogenital transmission of chlamydia and gonorrhoea in women. Enrollment is underway in EVOGUARD, a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of EVO100 for the prevention of these common STIs. Top-line results are expected in mid-2022.

EVOGUARD builds on positive, statistically significant results of a double-blind placebo-controlled Phase 2b clinical trial (AMPREVENCE). This landmark study met its primary and secondary endpoints, demonstrating a 50% relative risk reduction in chlamydia infection and a 78% relative risk reduction in gonorrhea infection compared to placebo. The AMPREVENCE manuscript was published in the prestigious peer-reviewed journal American Journal of Obstetrics and Gynecology  in 2021.

EVENTS
Tuesday, June 8, 2021
1:00pm - 1:25pm EDT

CEO Saundra Pelletier provided an update on the commercialization of Phexxi® (lactic acid, citric acid and potassium bitartrate), the develoment of lead product candidate EVO100 for the...

STOCK INFORMATION
NASDAQEVFM
PRESS RELEASES
Jul 28, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2021 on Wednesday,...

Jul 14, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today provided a preliminary look at Phexxi® (lactic acid, citric acid and potassium bitartrate) data for the second quarter of 2021 and revealed new...

Jun 1, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Saundra Pelletier, Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference 2021 as follows: Date: Friday,...

May 25, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on Tuesday, June 8, 2021 at 1:00 p.m. ET (10:00 a.m. PT)....

May 21, 2021

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year...

Read More